Pasithea Therapeutics Corp. (KTTAW) Operating Expenses (2021 - 2026)

Pasithea Therapeutics has disclosed Operating Expenses across 6 years of filings, most recently posting $5.7 million for Q2 2026.

• In Q2 2026, Operating Expenses rose 49.92% year-over-year to $5.7 million; the TTM figure through Jun 2026 stood at $24.0 million (up 74.15% YoY), while the FY2025 annual figure was $20.9 million, up 46.37% from the prior year.
• Operating Expenses came in at $5.7 million for Q2 2026 at Pasithea Therapeutics, up from $4.9 million in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $10.3 million in Q4 2025 to a low of $2.7 million in Q1 2022.
• Average Operating Expenses over 5 years is $4.3 million, with a median of $3.8 million recorded in 2023.
• Year-over-year, Operating Expenses jumped 397.01% in 2022 and slumped 36.69% in 2024.
• Over 5 years, Operating Expenses stood at $5.3 million in 2022, then declined by 3.27% to $5.1 million in 2023, then tumbled by 36.69% to $3.3 million in 2024, then surged by 214.65% to $10.3 million in 2025, then plunged by 44.29% to $5.7 million in 2026.
• Per Business Quant data, the three most recent Operating Expenses figures were $5.7 million in Q2 2026, $4.9 million in Q1 2026, and $10.3 million in Q4 2025.